Aarti Drugs Limited

NSEI:AARTIDRUGS Rapport sur les actions

Capitalisation boursière : ₹44.8b

Aarti Drugs Gestion

Gestion contrôle des critères 4/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Prakash Patil

Directeur général

₹27.8m

Rémunération totale

Pourcentage du salaire du PDG41.5%
Durée du mandat du directeur général39.8yrs
Propriété du PDG9.6%
Durée moyenne d'occupation des postes de direction11.3yrs
Durée moyenne du mandat des membres du conseil d'administration8.3yrs

Mises à jour récentes de la gestion

We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Sep 20
We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Recent updates

We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Sep 20
We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet

Sep 05
Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet

Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?

May 04
Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Feb 01
Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00

Jan 30
Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00

Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think

May 17
Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think

These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well

Nov 22
These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well

We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet

Aug 28
We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet

Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching

Aug 19
Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching

Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value

May 17
Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value

Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock

Apr 04
Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock

Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?

Mar 17
Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?

Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Mar 02
Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?

Feb 17
What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?

Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio

Feb 04
Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio

What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?

Jan 22
What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?

Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth

Jan 07
Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth

If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late

Dec 23
If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late

Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly

Dec 08
Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly

Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Nov 23
Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?

Nov 08
How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?

Here's What We Learned About The CEO Pay At Aarti Drugs Limited (NSE:AARTIDRUGS)

Oct 11
Here's What We Learned About The CEO Pay At Aarti Drugs Limited (NSE:AARTIDRUGS)

Analyse de la rémunération des PDG

Comment la rémunération de Prakash Patil a-t-elle évolué par rapport aux bénéfices de Aarti Drugs?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

₹2b

Jun 30 2024n/an/a

₹2b

Mar 31 2024₹28m₹12m

₹2b

Dec 31 2023n/an/a

₹2b

Sep 30 2023n/an/a

₹2b

Jun 30 2023n/an/a

₹2b

Mar 31 2023₹28m₹11m

₹2b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹2b

Jun 30 2022n/an/a

₹2b

Mar 31 2022₹31m₹10m

₹2b

Dec 31 2021n/an/a

₹2b

Sep 30 2021n/an/a

₹2b

Jun 30 2021n/an/a

₹2b

Mar 31 2021₹35m₹8m

₹3b

Dec 31 2020n/an/a

₹3b

Sep 30 2020n/an/a

₹2b

Jun 30 2020n/an/a

₹2b

Mar 31 2020₹19m₹7m

₹1b

Dec 31 2019n/an/a

₹1b

Sep 30 2019n/an/a

₹1b

Jun 30 2019n/an/a

₹888m

Mar 31 2019₹15m₹7m

₹898m

Dec 31 2018n/an/a

₹863m

Sep 30 2018n/an/a

₹887m

Jun 30 2018n/an/a

₹943m

Mar 31 2018₹14m₹7m

₹823m

Rémunération vs marché: La rémunération totale de Prakash ($USD 331.17K ) est dans la moyenne des entreprises de taille similaire sur le marché Indian ($USD 268.55K ).

Rémunération et revenus: La rémunération de Prakash a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Prakash Patil (77 yo)

39.8yrs

Titularisation

₹27,848,000

Compensation

Mr. Prakash Moreshwar Patil has been the Chairman of the Board of Aarti Drugs Limited since April 2014. Mr. Patil has been the Managing Director of Aarti Drugs Limited since June 1, 2007 and serves as its...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Prakash Patil
Chairmanno data₹27.85m9.59%
₹ 4.3b
Harshit Savla
Joint MD & Executive Director21.6yrs₹25.54m4.71%
₹ 2.1b
Adhish Patil
CFO & COO12.3yrs₹11.44m1.23%
₹ 552.1m
Rushikesh Deole
Company Secretary & Compliance Officer5.6yrs₹1.17mpas de données
Harit Shah
Whole-Time Directorno data₹25.54m4.43%
₹ 2.0b
Uday Patil
Whole-Time Director24.1yrs₹3.35m0.055%
₹ 24.5m
Rashesh Gogri
MD & Executive Director10.2yrs₹25.54m4.61%
₹ 2.1b
Dhanaji Kakade
Vice President of Technicalno datapas de donnéespas de données
Vishwa Savla
Managing Director of the Pinnacle Life Science Private Limitedless than a yearpas de données1.02%
₹ 458.3m

11.3yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de AARTIDRUGS est chevronnée et expérimentée (11.3 années d'ancienneté moyenne).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Prakash Patil
Chairman39.8yrs₹27.85m9.59%
₹ 4.3b
Harshit Savla
Joint MD & Executive Director37.8yrs₹25.54m4.71%
₹ 2.1b
Harit Shah
Whole-Time Director29.2yrs₹25.54m4.43%
₹ 2.0b
Uday Patil
Whole-Time Director24.1yrs₹3.35m0.055%
₹ 24.5m
Rashesh Gogri
MD & Executive Director12.3yrs₹25.54m4.61%
₹ 2.1b
Chandrakant Gogri
Chairman Emeritus12.3yrs₹43.00k1.86%
₹ 833.8m
Neha Gada
Independent Director2.5yrs₹155.00kpas de données
Sandeep Joshi
Additional Independent Directorless than a yearpas de donnéespas de données
Narendra Salvi
Non-Executive Director4.3yrs₹100.00kpas de données
Ankit Paleja
Independent Director3.1yrs₹215.00kpas de données
Bhaskar Thorat
Independent Director2.5yrs₹155.00kpas de données
Hasmukh Dedhia
Additional Independent Directorless than a yearpas de donnéespas de données

8.3yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de AARTIDRUGS sont considérés comme expérimentés (ancienneté moyenne 8.3 ans).